Junctional adhesion molecule-A (JAM-A) is a membranous cell-cell adhesion protein involved in tight-junction formation in epithelial and endothelial cells. Its overexpression in breast tumors has recently been linked with increased risk of metastasis. We sought to identify if JAM-A overexpression was associated with specific subtypes of breast cancer as defined by the expression of human epidermal growth factor receptor-2 (HER2), estrogen receptor (ER) and progesterone receptor. To this end, JAM-A immunohistochemistry was performed in two breast cancer tissue microarrays. In parallel, cross-talk between JAM-A, HER2 and ER was examined in several breast cell lines, using complementary genetic and pharmacological approaches. High JAM-A expression correlated significantly with HER2 protein expression, ER negativity, lower patient age, high-grade breast cancers, and aggressive luminal B, HER2 and basal subtypes of breast cancer. JAM-A and HER2 were co-expressed at high levels in vitro in SKBR3, UACC-812, UACC-893 and MCF7-HER2 cells. Knockdown or functional antagonism of HER2 did not alter JAM-A expression in any cell line tested. Interestingly, however, JAM-A knockdown decreased HER2 and ER-a expression, resulting in reduced levels of phospho-(active) AKT without an effect on the extracellular signal-related kinase phosphorylation. The downstream effects of JAM-A knockdown on HER2 and phospho-AKT were partially reversed upon treatment with the proteasomal inhibitor MG132. We conclude that JAM-A is co-expressed with HER2 and associates with aggressive breast cancer phenotypes. Furthermore, we speculate that JAM-A may regulate HER2 proteasomal degradation and activity, potentially offering a promise as a therapeutic target in HER2-positive breast cancers.
INTRODUCTION
Breast cancer is the most common form of cancer among women in North America and Europe. Each year, it is diagnosed in over one million women worldwide, and is the cause of death of over 450 000. 1 A major challenge in breast cancer treatment is to identify those patients most likely to develop recurrence so that appropriate therapy can be selected. Genomic studies have established five major breast cancer intrinsic subtypes (luminal A, luminal B, human epidermal growth factor receptor-2 (HER2)-enriched, basal-like and claudin-low) and a normal breast-like group that show significant differences in incidence, survival and response to therapy. [2] [3] [4] [5] Estrogen receptor (ER)-negative (HER2-enriched, basal-like and claudin-low) subtypes are associated with an increased risk of aggressive metastatic disease when compared with luminal (ER-positive) subtypes. HER2 is amplified in 20-30% of invasive breast cancers, which represent the luminal B and HER2-enriched subtypes. 6 HER2 oncogenic properties are thought to result from increased activation of several signaling pathways, including the extracellular signal-related kinase (ERK) cascade and the phosphoinositide 3-kinase/AKT pathway. 7 Therapeutic inhibition of HER2 function has been successfully applied to treat patients with HER2-positive breast cancer; [8] [9] [10] however, the efficacy of such strategies is limited by primary and acquired resistance. 7 Growth factor receptors are not the only membrane proteins of interest in the pathophysiology of breast cancer. Tight junction (TJ) proteins, such as Junctional adhesion molecule-A (JAM-A), CAR, claudin-3 and -4 have been shown to be overexpressed in breast cancer, [11] [12] [13] [14] [15] [16] [17] and may represent novel therapeutic targets. In normal breast tissue, these proteins are expressed at lower levels and confined predominately to areas of epithelial cell-cell contact. Enhanced expression in tumor cells may make TJ proteins interesting candidates for targeted delivery of cytotoxic agents, or for downregulation of signaling pathways related to oncogenic functions.
TJs along with adherens junctions form the apical junctional complex, which encircles the apex of epithelial and endothelial cells, and acts to maintain cell polarity by separating apical and basolateral compartments. 18 Of primary interest in our study is the TJ protein JAM-A, which has important functions in cellular adhesive processes, including TJ assembly, 19 cellular polarity, 20 the regulation of cell morphology, 21 angiogenesis, 22 platelet activation 23 and leukocyte migration. 24 Although it was initially reported that JAM-A expression on breast cancer cells might correlate inversely with invasive potential, 25 in fact, we 17 and others 26 more recently identified a significant association between JAM-A overexpression and poor prognosis in several large independent cohorts of breast cancer patients. Furthermore, JAM-A has been demonstrated to be a target of the microRNA miR-145, which is downregulated in breast cancer and whose overexpression decreases motility and invasive behavior in breast cancer cells. 27 In this study, we therefore sought to refine the link between JAM-A and aggressive tumor behavior, using breast cancer clinical data sets in conjunction with in vitro cell line models. We report that high JAM-A expression correlates significantly with HER2 protein expression, ER negativity and high-grade breast cancers. In breast cell lines co-expressing JAM-A and HER2, we present novel evidence that HER2 knockdown or treatment with Herceptin does not influence JAM-A protein expression. Conversely, we show that JAM-A knockdown reduces expression of HER2 and ER-a, with HER2 levels being partially restored by proteasomal inhibition in JAM-knockdown cells. JAM-A knockdown also exerts a selective effect on signaling through HER2 effector pathways, demonstrated as reductions in AKT, but not ERK, phosphorylation; and non-additive pro-apoptotic effects of JAM-A and an AKT inhibitor suggest that both proteins are in a linear pathway rather than acting separately. Collectively, our results suggest that JAM-A is a novel upstream regulator of HER2 degradation and activity, and that its overexpression may promote breast cancer progression in HER2-positive tumors. We submit that JAM-A offers promise not just as a novel biomarker of the HER2-positive breast cancer phenotype, but also as a drug target of the future.
RESULTS AND DISCUSSION
The intercellular adhesion protein JAM-A is expressed as a homodimer on epithelial and endothelial cell surfaces, and has been shown to have important physiological functions in numerous cellular adhesive processes. We and others have recently linked high breast epithelial expression of JAM-A with aggressive disease and poor outcome in breast cancer patients. 17, [26] [27] [28] We independently verified these findings on a small breast cancer tissue microarray of 48 tumor cores, in which tissue cores were scored 0, 1 þ , 2 þ or 3 þ according to the level of membranous JAM-A staining in tumor cells (Supplemental Figure S1 ). JAM-A expression was classified as low (0 or 1 þ ) in 28 tumors (58.3%) and high (2 þ or 3 þ ) in 20 tumors (41.7%). High JAM-A expression was significantly associated with low progesterone receptor expression (Po0.05), HER2 þ /estrogen/progesterone receptor-expressing breast cancers (Po0.05) and breast tumors of X2 cm in diameter (Po0.05; Supplemental Table S1 ). Furthermore, low JAM-A expression (0 or 1 þ ) was significantly associated with normal and benign tumors (blunt duct adenosis, fibrocystic changes and fibroadenomas), whereas high JAM-A expression (2 þ or 3 þ ) was significantly associated with invasive breast cancers (Po0.05; Supplemental Table S1 ). JAM-A expression in surrounding non-tumor tissue was low (approximately 1 þ ), and mainly confined to normal breast ducts and blood vessels (data not shown).
To further interrogate the subtypes of aggressive tumors associated with high JAM-A expression, we analyzed a larger tissue microarray of 167 tumor cores with known HER2 expression status. Tumor membranous expression of JAM-A was classified as low (0 or 1 þ ) in 75 tumors (44.9%) and high (2 þ or 3 þ ) in 92 tumors (55.1%). Examination of the relationship between JAM-A expression and other clinicopathological variables (Table 1) as examined by w 2 -test and Fisher's exact test on SPSS version 15.0 revealed that high JAM-A expression was significantly associated with HER2 protein expression (Po0.05), high tumor grade (Po0.001) and ER negativity (Po0.001). According to one molecular classification of breast cancers, 2 high JAM-A mRNA levels were also associated with the HER2 þ and basal subtypes of breast cancer (Po0.05). Using an online meta-analysis tool of published breast cancer microarray data sets, 29 we also confirmed a link between high (above median) JAM-A mRNA expression and reduced metastasis-free survival (Supplemental Figure S2A ; Po0.05) but not overall survival (Supplemental Figure S2B ) in HER2-positive patients.
As the number of ER-negative cases in our current study was small (n ¼ 21), these data were combined with a larger cohort from our previous work. 17 In the combined analysis of 437 patients (of which 80 of which were ER negative), high JAM-A protein expression (2 þ and 3 þ ) was significantly associated with ER negativity (Po0.001; Supplemental Table S2 ). Interestingly, JAM-A expression at 3 þ alone had only trended towards a correlation with ER negativity in our original study. 17 When JAM-A mRNA expression was assessed in relation to ER negativity using the online meta-analysis tool, 29 Kaplan-Meier analysis and the logrank test indicated that high (above median) JAM-A mRNA levels correlated significantly with reduced metastasis-free survival (Supplemental Figure S2C ; Po0.05) and reduced overall survival (Supplemental Figure S2D ; Po0.05) in ER-negative patients. These data confirm that high JAM-A expression in breast cancer is associated with aggressive breast tumor characteristics, and highlights a role for JAM-A as a possible biomarker.
As breast cancer is a heterogeneous disease, we screened JAM-A protein levels in a range of cell lines expressing different profiles of the clinicopathologically relevant molecular markers HER2 and ER-a (Supplemental Figure S3 ). All the HER2-positive cell lines expressed moderate to high levels of JAM-A, whereas the basallike ER-/HER2-negative cell line MDA-MB-231 expressed low levels of JAM-A. High JAM-A expression was also observed in non-transformed primary human mammary epithelial cells and non-tumorigenic MCF-10A cells, consistent with a role for JAM-A in normal cell-cell adhesion. In the normal context of polarized breast epithelial or endothelial barriers, JAM-A expression would be restricted to adhesive TJ complexes, in contrast to its diffuse staining pattern throughout the membranes of unpolarized epithelial cell populations in breast tumors. As JAM-A expression was high in several HER2-positive breast cancer cell lines, we questioned whether expression levels of one protein could regulate those of the other. We first knocked down HER2 expression in several breast cancer cell lines using a small interfering RNA (siRNA) approach. As shown by densitometric quantitation in Figure 1 , HER2 was successfully knocked down in SKBR3, UACC-893, MCF7-HER2 and LCC1 cells. A representative western blot for UACC-893 cells is shown. HER2 knockdown had no effect on JAM-A protein expression in the ER-negative cell lines SKBR3 and UACC-893. Interestingly, however, there was a partial (but statistically insignificant) reduction in JAM-A protein expression following HER2 knockdown in the ER-positive cell lines MCF7-HER2 30 and LCC1; Figure 1a ). Subtle reductions in JAM-A expression secondary to HER2 knockdown in ER-positive cells suggested that JAM-A expression levels may be regulated by those of ER-a. We thus knocked down ER-a in conjunction with HER2 in MCF7-HER2 and LCC1 cells to examine if JAM-A expression could be restored. As shown in the densitometric quantitation in Figure 1b , ER-a knockdown either alone or in conjunction with HER2 knockdown did not alter JAM-A protein expression in either cell line. A representative blot from LCC1 cells is shown. Furthermore, treatment with the anti-HER2 antibody Herceptin, which induced phosphorylation of HER2-1221 ( Figure 1c ) consistent with a mechanism of overactivating HER2 before increasing protein turnover, 31 did not significantly alter JAM-A expression in MCF7-HER2 cells. Chemical inhibition of HER2 with AG825 under conditions previously shown to inhibit stimulated HER2 phosphorylation 32 (data not shown) also did not alter JAM-A expression. Similarly, inhibition of ER-a with tamoxifen (4-hydroxy tamoxifen; OHT) or stimulation with 17-bestadiol (E 2 ; Figure 1d ) did not significantly alter JAM-A expression in MCF7-HER2 cells. Successful activation of ER-a in response to E2 was confirmed by increased expression of cyclin D1 (Figure 1d ) and by reduced cytoplasmic recovery of ER-a (data not shown).
Having observed no regulation of JAM-A protein expression following manipulation of HER2 or ER-a, we next tested the opposite strategy. JAM-A was transiently knocked down by siRNA in UACC-893 (data not shown), SKBR3, MCF7-HER2 and LCC1 cells. As shown by densitometric quantitation of western blots (Figure 2a from LCC-1 cells is shown. That this phenomenon relates specifically to JAM-A loss was confirmed by similar results using an independent siRNA to JAM-A in MCF7-HER2 cells (Supplemental Figure S5 ). To interrogate a potential link between ER and JAM-mediated regulation of HER2, we performed dual knockdowns of ER-a and JAM-A in ER-positive MCF7-HER2 cells. Interestingly, knockdown of ERa in conjunction with JAM-A partially rescued the reductions in HER2 protein levels induced upon JAM-A knockdown (Supplemental Figure S4) . We also tested whether functional antagonism of JAM-A using the dimerization-blocking antibody J10.4 could influence HER2 protein expression in SKBR3 or UACC-893 cells. As shown in Figure 2b , J10.4 successfully increased levels of p-GSK3-b (which are inversely proportional to JAM-A expression or function 33 ), but had no effect on the expression levels of JAM-A, HER2 or Y1221-phosphorylated HER2 in either cell line. A representative blot from UACC-893 cells is shown.
Following our observation that HER2 and ER-a protein expression was reduced upon knockdown of JAM-A, we next examined whether JAM-A knockdown caused increased turnover of ER-a, HER2, and its effectors AKT and ERK. JAM-A was transiently knocked down by siRNA in MCF7-HER2 cells, wherein we noted not only a significant reduction in HER2 and ER-a expression, but also that of phospho-AKT (dimethylsulphoxide condition in Figure 3a , quantitation in Figure 3b ). In contrast, there was a variable increase in ERK phosphorylation in response to JAM-A knockdown, but this was not statistically significant. As reduced AKT activity should promote apoptosis by limiting the expression of pro-survival and anti-apoptotic proteins, we also tested whether JAM-A knockdown increased apoptosis in MCF7-HER2 cells (Supplemental Figure S6) . Although significantly lower than that induced by the nuclease positive control (data not shown), apoptosis levels were slightly higher in cells transfected with JAM-A siRNA relative to a negative control siRNA. This supports recent observations of a link between JAM-A and apoptosis. 26 Interestingly, however, JAM-A knockdown did not have an additive effect on apoptosis induced by a specific AKT inhibitor (AKT inhibitor IV; Calbiochem/Merck Chemicals, Dharmstadt, Germany). This supports our hypothesis that AKT functions as a downstream survival effector of JAM-A in breast cancer cells.
To begin testing whether reductions in HER2 and pAKT expression downstream of JAM-A knockdown reflected proteasomal degradation, cells were treated with the proteasomal inhibitor MG132 4 h before lysis. The protein expression of HER2 and phospho-AKT was restored by MG132 treatment of JAM-A knockdown cells (Figure 3c ). However, ER-a and phospho-ERK levels were not restored under the same conditions. This suggested that JAM-A expression regulates that of HER2 and ERa through different mechanisms, with HER2 potentially being regulated through alteration of proteasomal degradation. This adds to increasing evidence that JAM-A regulates protein turnover through proteasomal degradation, as JAM-A knockdown has previously been shown to similarly reduce the protein expression of b1-integrin, 17, 28, 34 and aV-and a5-integrin. 28 Further studies are required to determine the specific proteasomal components implicated, but it is intriguing to speculate that JAM-A may also have the capability to likewise regulate the expression of other growth factor receptors/adhesion molecules relevant to breast cancer progression.
Interestingly, the HER2 effectors AKT and ERK were differentially regulated downstream of JAM-A manipulation in our models. Specifically, AKT phosphorylation was significantly reduced upon JAM-A knockdown and restored the following proteasomal inhibition, whereas ERK phosphorylation was not. A similar regulation of HER2 signaling has been reported following adenine nucleotide translocase-2 knockdown, which increases HER2 degradation through suppression of HSP90 functions, and results in inhibition of the phosphoinositide 3-kinase /AKT signaling pathway. 35 Active AKT has also been shown to regulate ERK activation by phosphorylating and inhibiting Raf-1, a kinase which activates ERK through MEK. 36 Our results suggest that JAM-A knockdown regulates AKT indirectly by first altering the protein levels of its upstream regulator HER2, which in turn would be predicted to alter AKT phosphorylation levels. AKT has been shown to promote cancer cell invasion, cell survival, increased motility and metalloproteinase production, as well as promoting resistance to trastuzumab and tamoxifen in breast cancer cells. [37] [38] [39] Thus, one might conversely predict that overexpression of JAM-A in breast cancer facilitates tumorigenic signaling by enhancing protein expression of molecules, such as HER2, promoting aggressive breast cancers 17 associated with increased levels of AKT activity and downstream enhancement of survival and motility. Furthermore, the pharmacological reduction of JAM-A signaling may have benefit in reducing metastatic risk, as we 17, 28 and others 27 have shown that JAM-A knockdown or functional antagonism decreases breast cancer cell migration, an early event in metastasis.
It is interesting to note that ER-a expression was regulated by JAM-A in the ER-positive cell lines tested, whereas our tissue microarray data demonstrated a link between high JAM-A expression and ER-a negativity. On the basis of the tissue microarray data, we had hypothesized that ER would negatively regulate JAM-A expression, yet pharmacological interference with ER-a signaling using estrogen or tamoxifen did not regulate JAM-A expression in the cell lines tested. This intriguing difference illustrates the importance of considering cell line data in conjunction with more pathophysiologically representative tissue data from a large number of patients. However, as stimulation of ER-b with estrogen has been shown to upregulate JAM-A in intestinal cells, 40 we speculate that a level of unexplored crosstalk exists. Given the functionally opposing roles of ER-a and -b in breast tissue, it is possible that ER-a-negative tissue may express ER-b; however, a larger ER-negative cohort of tissue samples would be needed to answer this question.
In conclusion, we have shown that JAM-A is upregulated in HER2-positive, ER-negative breast cancers and associated with more aggressive breast cancers. Our data and another recent report 26 did not find JAM-A to be an independent prognostic factor in breast cancer. However, we suggest that combined analysis of JAM-A expression with HER2 or ER status may be most meaningful, as patients with high mRNA levels of JAM-A had an increased risk of developing distant metastases if they were HER2-positive (hazard ratio ¼ 2.48) or ER-negative (hazard ratio ¼ 2.13). Although high JAM-A expression in tissue microarrays correlates with ER negativity, we show for the first time that JAM-A regulates HER2 and ER-a levels, with HER2 levels being potentially regulated through proteasomal degradation in breast cell lines. Our data also indicate that observed reductions in HER2 downstream of JAM-A prevent downstream activation of AKT. This effect on AKT following JAM-A knockdown suggests that therapeutics targeting JAM-A expression or signaling may offer new treatment options for aggressive tumors overexpressing JAM-A and/or HER2. ABBREVIATIONS HER2, human epidermal growth factor receptor-2; JAM-A, junctional adhesion molecule-A. 
